Abstract
Darolutamide is one of the androgen receptor inhibitors used in the treatment of castration-resistant prostate cancer. Based on the results of the multicenter phase III study ARAMIS, it is currently indicated for the treatment of non-metastatic castration-refractory prostate cancer with a high risk of progression to metastatic disease.
It is taken orally at a dose of 600 mg twice a day. At the same time, maintenance of castration testosterone levels is indicated.
The treatment was well tolerated in most patients.